Market LIVE
Published markets; coverage varies by country
Product profile · United States

ESBRIET

 ·  Patent Litigation & Settlement History ↓

IngredientPIRFENIDONE
Application typeNDA
Application208780
Product003
Dosage formTABLET
RouteORAL
Strength801MG
Approval date2017-01-11
Marketing statusPrescription
Status event—
ApplicantLEGACY
Product source

Current GenericRadar decision

Year2022
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2022-01-25
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2022-01-25
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
77677002027-12-18U U-2080———
———
84206742027-12-18U U-2079———
———
83831502028-05-10DP/U U-2361———
———
75667292029-04-22U U-2078———
———
75667292029-04-22U U-2077———
———
76357072029-04-22U U-2073———
———
76357072029-04-22U U-2076———
———
76357072029-04-22U U-2072———
———
76357072029-04-22U U-2075———
———
76357072029-04-22U U-2074———
———
76357072029-04-22U U-2083———
———
85924622029-04-22U U-2060———
———
85924622029-04-22U U-2059———
———
85924622029-04-22U U-2057———
———
85924622029-04-22U U-2058———
———
85924622029-04-22U U-2056———
———
85924622029-04-22U U-2063———
———
85924622029-04-22U U-2055———
———
85924622029-04-22U U-2062———
———
85924622029-04-22U U-2061———
———
86097012029-04-22U U-2069———
———
86097012029-04-22U U-2064———
———
86097012029-04-22U U-2067———
———
86097012029-04-22U U-2070———
———
86097012029-04-22U U-2065———
———
86097012029-04-22U U-2066———
———
86097012029-04-22U U-2068———
———
78163832030-01-08U U-2050———
———
78163832030-01-08U U-2042———
———
79106102030-01-08U U-2048———
———
79106102030-01-08U U-2049———
———
80130022030-01-08U U-2082———
———
80130022030-01-08U U-2047———
———
80844752030-01-08U U-2052———
———
80844752030-01-08U U-2054———
———
83187802030-01-08U U-2046———
———
83187802030-01-08U U-2081———
———
86480982030-01-08U U-2052———
———
86480982030-01-08U U-2051———
———
87541092030-01-08U U-2053———
———
87789472033-08-30U U-2045———
———
87789472033-08-30U U-2044———
———
101886372037-03-28DP ————
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
212615 / 002APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——GRANULES INDIANEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212730 / 002FINAL_APPROVAL · FINAL_APPROVED2022-01-25—ACCORD HEALTHCARE INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212759 / 002FINAL_APPROVAL · FINAL_APPROVED2022-01-25—TEVA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212570 / 002FINAL_APPROVAL · FINAL_APPROVED2022-03-25—AMNEAL EU LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212560 / 002FINAL_APPROVAL · FINAL_APPROVED2022-04-28—SANDOZ INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212680 / 002FINAL_APPROVAL · FINAL_APPROVED2022-05-18—MICRO LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212708 / 002FINAL_APPROVAL · FINAL_APPROVED2022-05-20—ALEMBIC PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212772 / 002FINAL_APPROVAL · FINAL_APPROVED2022-05-24—MSN LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212722 / 003FINAL_APPROVAL · FINAL_APPROVED2022-07-19—LAURUS LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212747 / 003FINAL_APPROVAL · FINAL_APPROVED2022-07-21—AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212078 / 002FINAL_APPROVAL · FINAL_APPROVED2022-08-01—SCIEGEN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212674 / 002FINAL_APPROVAL · FINAL_APPROVED2022-09-21—HETERO LABS LTD UNIT VNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212709 / 002FINAL_APPROVAL · FINAL_APPROVED2023-05-31—APOTEX INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212403 / 002FINAL_APPROVAL · FINAL_APPROVED2023-08-23—CHARTWELL RX SCIENCES LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212596 / 002FINAL_APPROVAL · FINAL_APPROVED2025-08-11—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 14 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
212730 / 002ACCORD HEALTHCARE INCFINAL_APPROVAL · FINAL_APPROVED2022-01-25 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212759 / 002TEVA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2022-01-25 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212570 / 002AMNEAL EU LTDFINAL_APPROVAL · FINAL_APPROVED2022-03-25 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212560 / 002SANDOZ INCFINAL_APPROVAL · FINAL_APPROVED2022-04-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212680 / 002MICRO LABS LTDFINAL_APPROVAL · FINAL_APPROVED2022-05-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212708 / 002ALEMBIC PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2022-05-20 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212772 / 002MSN LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2022-05-24 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212722 / 003LAURUS LABS LTDFINAL_APPROVAL · FINAL_APPROVED2022-07-19 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212747 / 003AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2022-07-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212078 / 002SCIEGEN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2022-08-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212674 / 002HETERO LABS LTD UNIT VFINAL_APPROVAL · FINAL_APPROVED2022-09-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212709 / 002APOTEX INCFINAL_APPROVAL · FINAL_APPROVED2023-05-31 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212403 / 002CHARTWELL RX SCIENCES LLCFINAL_APPROVAL · FINAL_APPROVED2023-08-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212596 / 002AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2025-08-11 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2022-01-25TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.